The patient with metastatic melanoma that achieved a PR had a tumor with molecular alterations (NRAS mutation and copy-number loss at the INK4 locus) that induced aberrant CDK4 and CDK6 activation [53]. Here, CDKN2A is linked to metastatic melanoma.